To assess the mortality and resource utilization that results from acute renal failure associated with amphotericin B therapy, 707 adult admissions in which parenteral amphotericin B therapy was given were studied at a tertiary-care hospital. Main outcome measures were mortality, length of stay, and costs; we controlled for potential confounders, including age, sex, insurance status, baseline creatinine level, length of stay before beginning amphotericin B therapy, and severity of illness. Among 707 admissions, there were 212 episodes (30%) of acute renal failure. When renal failure developed, the mortality rate was much higher: 54% versus 16% (adjusted odds of death, 6.6). When acute renal failure occurred, the mean adjusted increase in length of stay was 8.2 days, and the adjusted total cost was $29,823. Although residual confounding exists despite adjustment, the increases in resource utilization that we found are large and the associated mortality is high when acute renal failure occurs following amphotericin B therapy.
Systemic fungal infections are a serious problem and infected patients have a high mortality rate, especially immunocompromised patients [1] . Even among patients with candidemia, which is relatively responsive to therapy compared with other fungal infections, mortality rates have ranged from 46% to 75% [2] [3] [4] [5] [6] [7] . Invasive aspergillosis has an even higher mortality rate and remains a leading cause of morbidity and mortality in patients with cancer, especially among those who have undergone bone marrow transplantation (BMT) [8] .
Although amphotericin B has long been a mainstay of therapy for systemic fungal infections, it has many adverse effects, including fever; chills; nausea and vomiting; a variety of electrolyte abnormalities, including hypokalemia, hypomagnesemia, hypernatremia, and metabolic acidosis; and most important, acute renal failure [9] [10] [11] [12] [13] [14] . It appears that this nephrotoxicity is mediated in part through its direct toxic effect on renal tubular cells, resulting in acute tubular necrosis [15] ; vasoconstriction is also induced, with both processes reducing glomerular filtration [15] [16] [17] [18] [19] . There are no specific treatments available to reverse the acute renal failure associated with amphotericin B, although salt loading (when tolerated) has been used with some success as a prophylactic measure [20] [21] [22] . This acute renal failure is often dose-limiting, is sometimes irreversible, and can prolong length of stay and increase costs.
Considering the frequency of the complication, relatively few data are available regarding the mortality rates associated with acute renal failure from any cause [23, 24] , and it remains controversial whether patients die with renal failure caused by their underlying disease or directly from this complication. One study found that acute renal failure that occurred after coronary artery bypass surgery was associated with a 7.9-fold increased odds of death [23] , and another study of BMT recipients demonstrated large differences in mortality with worsening renal impairment [24] .
The reported frequency of acute renal failure associated with amphotericin B has varied widely [14, 18] . A meaningful decrement in renal function has been reported to occur in up to 80% of patients who receive the drug, and it is almost inevitable in patients who receive a cumulative dose of 15 g. However, much smaller total doses are currently used. For example, in one recent study of 102 patients in a community hospital, the mean cumulative dose of amphotericin used was !200 mg, and the maximum dose was 840 mg; in this population, only 15% of the patients developed acute renal failure [14] .
Less toxic antifungal agents, including imidazoles, triazoles, and lipid formulations of amphotericin [1, [25] [26] [27] , have been developed. Although these drugs appear to be less nephrotoxic [25, 27] , their efficacy compared with that of amphotericin B has not been demonstrated for invasive infections such as aspergillosis. In addition, these drugs are typically more expensive than amphotericin B. Evaluation of the costs and risks of amphotericin toxicity, along with data about the relative efficacy and costs of other antifungals, could help inform decisions about which patients should receive newer, more costly but less nephrotoxic agents. Therefore, we performed a retrospective cohort study that investigated the frequency of acute renal failure among patients who were receiving parenteral amphotericin B and its associated increase in mortality rate and increases in use of resources.
PATIENTS AND METHODS
Study site. The study took place at a tertiary-care teaching hospital, Brigham and Women's Hospital, which is located in Boston and has ∼35,000 admissions per year. The hospital has a large oncology service and includes an allogeneic BMT unit. Patients were initially identified by use of the hospital's billing database by finding patients who had been billed for amphotericin.
Study population. The unit of analysis was the admission. All 1192 adult patients admitted from 17 May 1993 through 22 April 1997 who received amphotericin B were eligible. Only the first episode in which a patient was exposed to amphotericin B during an admission was included. Admissions were excluded if the patient had undergone dialysis before beginning therapy ( ) or if amphotericin B was given by a nonparenteral n p 52 (i.e., bladder irrigation) route ( ). Sixty-four patients n p 433 who were given both amphotericin B and lipid formulations of amphotericin were not excluded. Thus, the study population included 707 admissions in which parenteral amphotericin B therapy was given.
Data. Data were obtained from both hospital billing and clinical databases. The baseline serum creatinine level was the first value on the day that amphotericin B was started or the last value before the start date. The final creatinine level was the last value after the amphotericin B start date, and the highest creatinine level was the first peak value after starting amphotericin B. Data on length of stay and categories of charges were obtained from the hospital's fiscal database. Categories of charges included intensive care, routine care, surgical service, clinical laboratory (e.g., chemistry, hematology), patient laboratory (e.g., catheterization laboratory, electrocardiography), blood bank, pathology, pharmacy, radiology, respiratory, transplant service, rehabilitation, other ancillary service, all other inpatient service, and ambulatory services. Demographic and other data, including age, sex, race, insurance status (classified as fee-for-service, health maintenance organization, Medicare, Medicaid, or none), total dose of amphotericin B therapy, concomitant medications including aminoglycoside and cyclosporine therapy, and discharge diagnosis-related group (DRG) were collected from the hospital's clinical database. To adjust for severity of illness, we used year-specific DRG weight [28] .
Main outcome measures. Acute renal failure was defined as a 50% increase in the baseline creatinine level, with a peak of у2.0 mg/dL. Length of stay was measured in days after initiation of amphotericin B therapy. Costs were estimated by multiplying charges by year-specific cost-to-charge ratios for key categories of charges, including intensive care, routine care, surgical service, clinical laboratory, patient laboratory, blood bank, pathology, pharmacy, radiology, respiratory, transplant service, rehabilitation, other ancillary service, all other inpatient service and ambulatory service [29] . In secondary analyses, acute renal failure was divided into categories: "severe" was defined as a doubling of baseline creatinine level, with a peak of у3.0 mg/dL, and "significant" was defined as meeting the definition for acute renal failure but not the definition for severe renal failure.
Analyses. Univariate comparisons between admissions in which acute renal failure developed and those in which it did not were made by use of the Wilcoxon rank sum statistic for nonnormal continuous variables and the x 2 statistic for categorical variables. Multivariate comparisons were made by use of generalized linear modeling, with length of stay and costs as the dependent variable and acute renal failure as the main covariate of interest, adjusting for age, sex, baseline serum creatinine level, insurance status, DRG weight, and length of stay before beginning amphotericin therapy. In a secondary analysis, we repeated the above analyses with use of significant and severe renal failure as the primary covariates.
The final regression models to predict length of stay and total costs were checked for outliers and influential points [30] . Outliers were identified by examining the jackknife residuals for all patients with Studentized residuals 12 in absolute magnitude; 9 episodes were found. No influential point was de- tected; the largest value of Cook's distance was 0.23. We therefore present analyses without excluding outliers. All analyses were done with SAS software, version 6.12 (SAS) [31] .
RESULTS
Altogether, we evaluated 551 patients, with a total of 707 admissions in which systemic amphotericin B was given and no exclusion criterion was present (table 1) . Among these 707 episodes, acute renal failure developed in 212 (30%). Among these 212 acute renal failure episodes, 89 (13%) met the criteria for severe acute renal failure (doubling of the baseline creatinine level, with a peak of у3.0 mg/dL), and 123 (17%) were significant (a 50% increase in baseline creatinine level, with a peak of у2.0 mg/dL but not reaching the severe category) .
The mean duration of amphotericin therapy was 14.8 ‫ע‬ days (median, 10 days; 25% and 75% quartiles, 5 and 19 17.5 days), and the mean amount of amphotericin per course was 15 g ). The risk of acute renal failure was significantly related to an increase in the total dose of amphotericin that was given (P for trend, .001), with a frequency of 23% in the lowest dose group and 42% in the highest dose group (figure 1). Patients who developed acute renal failure were more often male ( ) and had slightly higher baseline creatinine levels P p .001 than did patients who did not develop acute renal failure ( mg/dL; , Wilcoxon). The mean final creati-D p 0.1 P p .02 nine level was 2.5 mg/dL (95% CI, 2.3-2.7 mg/dL; median, 2.2 mg/dL; 25% and 75% quartiles, 1.6 and 3 mg/dL) in patients who developed acute renal failure, and the mean highest creatinine level was 3.3 mg/dL (95% CI, 3.1-3.5 mg/dL; median, 2.9 mg/dL; 25% and 75% quartiles, 2.3 and 3.8 mg/dL).
The mortality rate in the study group was high; among 707 admissions, 194 (27%) resulted in death. The mortality rate was much higher in episodes in which acute renal failure developed: 54% versus 16% ( ). In a crude analysis, acute P p .001 renal failure was associated with an OR of 6.2 for death (95% CI, 4.3-9.0). This increased risk of death associated with acute renal failure was essentially unchanged by adjusting for age, sex, baseline serum creatinine level, insurance status, DRG weight, and length of stay before the patient began amphotericin B therapy (OR, 6.6; 95% CI, 4.5-9.7). Because the creatinine level could have increased as a premorbid phenomenon, we also evaluated the effect of censoring the creatinine values from the last 2 days of admission; in this analysis, 50% of patients with acute renal failure died, compared with 19% of the control group (still ). P p .001 Univariate resource utilization analyses. For most of the categories, the average hospital costs per admission were significantly higher for patients who had episodes with acute renal failure than for those who did not (table 2) . These included the combination of intensive care unit and routine care (cost per patient, $20,224), clinical laboratory ($2088), patient laboratory ($456), blood bank ($5380), pathology ($55), pharmacy ($8166), radiology ($2978), respiratory ($1059), and other inpatient service ($283). In crude analyses, the mean length of stay ( ) for admissions with acute renal failure was mean ‫ע‬ SE days, versus days for admissions without 27.8 ‫ע‬ 2.2 17.8 ‫ע‬ 0.7 acute renal failure, for a mean difference of 10 days. For total costs, the mean difference was $44,557 per patient (table 3) .
Multivariate resource utilization analyses. We subsequently performed multiple regression analyses, adjusting for potential confounders, including age, sex, baseline serum creatinine level, insurance status, DRG weight, and length of stay before beginning amphotericin B therapy (table 3) . In these analyses, the mean increase in length of stay associated with acute renal failure was 8.2 days ( ). For total costs, the P ! .0001 mean adjusted increase was $29,823 per patient ( ). P ! .0001 There was no significant difference between significant and severe renal failure for either length of stay after beginning amphotericin or total costs.
For a patient beginning amphotericin B therapy, factoring in the incidence of acute renal failure, the mean expected costs associated with nephrotoxicity alone would be $8947, and the expected increase in length of stay would be 2.5 days.
Because there were many deaths in the study group, and patients who died could have lower or higher costs than survivors, we repeated the above analyses after excluding patients who died. For the survivors, the adjusted mean difference for length of stay after starting amphotericin between the acute renal failure and normal groups was 13.6 days (5.4 days longer than in the analysis including all patients), and the adjusted mean difference in costs did not change meaningfully ($30,051 for survivor-only analysis vs. $29,823 including all patients).
DISCUSSION
These data suggest that patients who received parenteral amphotericin B therapy and developed acute renal failure had substantially higher mortality, length of stay, and costs than did those who did not have acute renal failure, even after adjusting for potential confounders. In undertaking this study, we recognized that not all acute renal failure that developed among patients who were treated with amphotericin B was attributable to drug-related nephrotoxicity. Residual confounding by indication and severity of illness still exists despite these adjustments. However, for the resource analyses, the magnitude of the difference that persisted after adjustment suggests that amphotericin B contributed an important part of the excess. These data further suggest that measures to decrease the frequency of acute renal failure, such as use of alternative therapies or strategies to decrease the nephrotoxicity of amphotericin B, could reduce the rate of mortality and costs. It would be especially useful to be able to identify prospectively patients who are at high risk of renal failure associated with amphotericin B to allow targeting of preventive measures. The mortality rate among patients with acute renal failure in this study was very high, and the OR was essentially unchanged by adjustment. In general, relatively few data are available about the epidemiology of acute renal failure in hospitalized patients. Although it is unclear whether acute renal failure causes death or accompanies it, data suggest that the development of acute renal failure is associated with much worse outcomes after coronary artery bypass surgery [23] and BMT [24] . In their analysis of BMT recipients, Zager et al. [24] found that the crude mortality among patients who required dialysis was 84%, whereas it was 37% in patients whose serum creatinine level doubled and only 17% in patients whose creatinine level did not double. In addition, amphotericin B use was independently correlated with renal failure requiring dialysis [24] .
Amphotericin B has long been the mainstay of therapy for serious fungal infections, although it has a variety of toxicities, the most important of which is renal. Among newer therapies, lipid-associated amphotericin preparations have been reported to be less nephrotoxic [25, 32, 33] , although only limited data are available regarding therapeutic equivalency, and these preparations are more expensive than the standard preparations. Imidazoles are also useful agents; however, may clinicians are reluctant to use them as first-line therapy for serious infections, such as aspergillosis, and recent studies indicate increasing resistance to these agents, especially in candidal infections caused by species other than Candida albicans. The limitations of these existing therapies have further generated interest in the development of new classes of agents. However, critical evaluation of existing and future antifungal agents will need to include consideration of the frequency of acute renal failure as well as drug costs and comparative efficacy.
The cost estimates from this study may help health organizations balance the costs of these newer agents with the potential economic offsets that may be available from reducing the risk of nephrotoxicity. Assuming the incidence of nephrotoxicity and costs with amphotericin B observed in this study, a fungicidal agent that could result in complete elimination of nephrotoxicity would be associated with a cost offset of $8947 per patient and a decrease in length of stay of 2.5 days. Given the results observed in this study, for every 10% reduction in the rate of acute renal failure there would be an expected $890 reduction in inpatient treatment costs and a 0.25 day shorter length of stay over a population, although these figures could vary substantially for individual patients according to their risk of acute renal failure.
The frequency of acute renal failure associated with amphotericin B has varied widely from study to study [14, 18, [34] [35] [36] , depending in part on the dose of amphotericin given and on the definition used. By use of a broader definition than we used (peak serum creatinine level of у1.6 mg/dL, with an increase of у0.5 mg/dL during therapy), Pathak et al. [14] reported a rate of only 15%. That study took place in a community hospital, and, therefore, the patients may have been less ill than the patients in the current study.
The estimates of resource utilization associated with acute renal failure from this study are important, especially because they are so high. By comparison, the cost of an average adverse drug event is only ∼$2595 [29] versus $29,823 shown in this study. Especially in this era of cost containment, when the pharmacy's costs are often viewed within a "silo," the costs of adverse outcomes, such as renal failure, that fall outside the drug budget may be ignored. Thus, these data underscore the importance of considering drug costs from the broader perspective.
This study has a number of limitations. The data came from 1 tertiary-care institution, and the results may not be generalizable to other institutions or settings. As noted earlier, confounding by indication for therapy may exist. In a chart review of 231 of these patients, 86 (37%) received amphotericin B because of documented fungal infection, whereas for the remainder, the indication was empirical, presumed infection, usually in the setting of fever and neutropenia. Also, confounding by severity of illness may exist, even though we adjusted by DRG weight. For the mortality analyses, we did not have data about severity scores, for example.
We conclude that the incidence of acute renal failure associated with amphotericin B therapy is high, that death occurs frequently in patients who develop acute renal failure while receiving the drug, and that the additional length of stay and costs associated with receiving this therapy are very high. These data make clear the costs of this complication and suggest that alternative agents that reduce its frequency may be cost-effective, especially among patients at high risk of developing renal failure.
